H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharmaceutical Holding (BHVN)

December 26, 2025 6:40 AM EST Send to a Friend
H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $11.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login